DACETUZUMAB
Dacetuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target tumor necrosis factor receptor superfamily member 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 2 | — | — | — | 5 |
| Lymphoma | D008223 | — | C85.9 | 2 | 2 | — | — | — | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 2 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 1 | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 3 | — | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | 2 | — | — | — | — | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 2 | — | — | — | — | 2 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 2 | — | — | — | — | 2 |
| Immunoproliferative disorders | D007160 | — | C88.9 | 2 | — | — | — | — | 2 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | — | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | 1 | — | — | — | — | 1 |
| Hemostatic disorders | D020141 | — | — | 1 | — | — | — | — | 1 |
| Paraproteinemias | D010265 | — | D47.2 | 1 | — | — | — | — | 1 |
| Hemorrhagic disorders | D006474 | — | D69.9 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DACETUZUMAB |
| INN | dacetuzumab |
| Description | Dacetuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743005 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | UT59FF4T5X (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CD40
CD40
Organism
Homo sapiens
Gene name
CD40
Gene synonyms
TNFRSF5
NCBI Gene ID
Protein name
tumor necrosis factor receptor superfamily member 5
Protein synonyms
B cell surface antigen CD40, B cell-associated molecule, B-cell surface antigen CD40, Bp50, CD40, CD40 molecule, TNF receptor superfamily member 5, CD40L receptor, CDw40
Uniprot ID
Mouse ortholog
Cd40 (21939)
tumor necrosis factor receptor superfamily member 5 (Q99NE3)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 295 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use